FindTrial
Sign In

Screening for Severe Combined Immunodeficiency Disease using Umbilical Cord Absolute Lymphocyte Count

UTILITY OF UMBILICAL CORD BLOOD ABSOLUTE LYMPHOCYTE COUNT IN SCREENING FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE â?? A ONE YEAR LONGITUDINAL STUDY AT KLEs DR PRABHAKAR KORE HOSPITAL AND MRC BELAGAVI

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/04/052123
Enrollment
1441
Registered
2023-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

ABHISHEK CHANDIRA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newborns more than 32 weeks period of gestation

Exclusion criteria

Exclusion criteria: 1) Newborns less than 32 weeks period of gestation 2) Antenatal use of steroids or immunosuppressive medications for more than 5 days. 3) Trisomy 21 4) Hydrops

Design outcomes

Primary

MeasureTime frame
To estimate the incidence of absolute lymphopenia in Umbilical Cord Blood samples of newborns and its utility in Screening for Severe Combined Immunodeficiency Disease(SCID) Timepoint: Umbilical cord blood EDTA sample of newborns at birth—

Secondary

MeasureTime frame
1) To evaluate other causes of lymphopenia in newborns. 2) To study the impact of early detection of SCID on improvement in the patient outcome by prompt referral for curative management Timepoint: Follow up after 1 month if required—

Countries

India

Contacts

Public ContactAbhishek Chandira

JNMC, KLE University

abhilasha.pedia@gmail.com9686187023

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026